Healthcare
4DMedical Limited(FDMDF)
Live Price
Offline$2.70
+0.00% today
1Y Change
+1084.73%
Window
Jun 25, 2025 โ Jun 19, 2026
- Market Cap
- $2.25B
- Revenue Growth
- +91.9%
- EPS Growth
- +35.5%
- Dividend Yield
- 0.0%
Coverage: 255 bars ยท Jun 25, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
4DMedical Limited (FDMDF) is a Healthcare stock with a market cap of $2.25B and listed on OTC. The stock last traded around $2.70 and up 1084.7% across the available one-year price window (Jun 25, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of +91.9%, EPS growth of +35.5%, a dividend yield of 0.0%. What stands out right now is revenue +91.9%, EPS +35.5%, free cash flow -10.9% with operating margin -1166.3% and ROIC -37.3%. Valuation already assumes a fairly strong business story at price/sales 520.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FDMDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+91.9% vs +7.6% peer median
Operating Margin
Below sector median
-1166.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 26, 2026 with an EPS surprise of -615.6% and a revenue surprise of -4.9%.
The operating story is still moving forward
Revenue is running at +91.9% and EPS at +35.5%, with operating margin around -1166.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +17.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 26, 2026 | -615.6% | +0.0% | +52.1% | +44.3% |
2025 Aug 28, 2025 | โ | +0.0% | +0.0% | +291.2% |
2025 Feb 26, 2025 | +22.5% | +0.0% | +0.0% | -28.7% |
Benchmark Edge
FDMDF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FDMDF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FDMDF Max Drawdown
-55.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FDMDF and SPY.
Company Overview
4DMedical Limited
Other OTC
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
- Leadership
- Andreas Fouras
- IPO Date
- Feb 2, 2021
- Employees
- 145
- Street Address
- Melbourne Connect
- Mailing
- Carlton, VIC, 3053
- Region
- Carlton, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9545 5940
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 520.0
- Price/Book
- โ
Growth
- Revenue
- +91.9%
- EPS
- +35.5%
- Free Cash Flow
- -10.9%
Profitability
- Gross Margin
- -396.6%
- Operating Margin
- -1166.3%
- Net Margin
- -3684.6%
- ROE
- -890.8%
- ROIC
- -37.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 6.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.